Danaher CorporationDHREarnings & Financial Report
Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments,...
DHR Q3 2025 Key Financial Metrics
Revenue
$6.1B
Gross Profit
$3.5B
Operating Profit
$1.2B
Net Profit
$908.0M
Gross Margin
58.2%
Operating Margin
19.1%
Net Margin
15.0%
YoY Growth
4.4%
EPS
$1.27
Financial Flow
Danaher Corporation Q3 2025 Financial Summary
Danaher Corporation reported revenue of $6.1B for Q3 2025, with a net profit of $908.0M (15.0% margin). Cost of goods sold was $2.5B, operating expenses totaled $2.4B.
Key Financial Metrics
| Total Revenue | $6.1B |
|---|---|
| Net Profit | $908.0M |
| Gross Margin | 58.2% |
| Operating Margin | 19.1% |
| Report Period | Q3 2025 |
Danaher Corporation Annual Revenue by Year
Danaher Corporation annual revenue history includes year-by-year totals (for example, 2024 revenue was $23.9B).
| Year | Annual Revenue |
|---|---|
| 2024 | $23.9B |
| 2023 | $27.6B |
| 2022 | $30.3B |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.41B | $5.80B | $5.74B | $5.80B | $6.54B | $5.74B | $5.94B | $6.05B |
| YoY Growth | -10.2% | -19.1% | -19.8% | -15.6% | 2.1% | -0.9% | 3.4% | 4.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $84.49B | $83.40B | $78.56B | $80.61B | $77.54B | $79.12B | $81.62B | $79.90B |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $53.49B | $53.44B | $49.90B | $51.30B | $49.54B | $50.85B | $52.33B | $51.07B |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $1.62B | $1.74B | $1.42B | $1.51B | $2.02B | $1.30B | $1.34B | $1.66B |
Other Health Care Companies
A
Agilent Technologies
Revenue
$1.9B
Net Profit
$434.0M
TECH
Bio-Techne
Revenue
$295.9M
Net Profit
$38.0M
CRL
Charles River Laboratories
Revenue
$994.2M
Net Profit
$-276.6M
IQV
IQVIA
Revenue
$4.4B
Net Profit
$514.0M
MTD
Mettler Toledo
Revenue
$1.1B
Net Profit
$285.8M
TMO
Thermo Fisher Scientific
Revenue
$11.1B
Net Profit
$1.6B
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
ABBV
AbbVie
Revenue
$15.8B
Net Profit
$186.0M
ALGN
Align Technology
Revenue
$995.7M
Net Profit
$56.8M
AMGN
Amgen
Revenue
$9.9B
Net Profit
$1.3B